MedTrace Logo

The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing

NCT01128556 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-07-08

No results posted yet for this study

Summary

To evaluate the effect of BEPREVE compared to a REFRESH Tears Lubricant eye drop on the measurement of the wheal and flare from histamine skin prick testing. This is an open label, two-week, post-marketing study conducted on histamine responsive patients.

Conditions

  • Histamine Responsive Allergy Patients

Interventions

DRUG

Bepreve

Bepreve (bepotastine besilate ophthalmic solution 1.5%) one drop in each eye twice daily

DRUG

Refresh Tears

Refresh Tears one drop to each eye twice daily for 7 days after the conclusion of Bepreve treatment

Sponsors & Collaborators

  • North Texas Institute for Clinical Trials

    lead OTHER

Principal Investigators

  • Bob Q Lanier, MD · North Texas Institute for Clinical Trials

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01128556 on ClinicalTrials.gov